Albumedix drug delivery technology used by CSL Behring to achieve 14 day dosing for haemophilia B therapy

Veltis offers a highly versatile drug delivery platform that improves treatment options and patient quality of life.

Proprietary Veltis technology used in FDA approved Idelvion.

“The adoption of Albumedix’s Veltis technology by CSL Behring marks a further milestone for our half-life extension platform”, commented Peter Rosholm, CEO, Albumedix. “This announcement follows the successful use of the technology by GlaxoSmithKline in its Tanzeum and Eperzan branded therapies for type 2 diabetes. We consider the authorization of Idelvion as further proof that Veltis can offer true benefits to patients in the area of haemophilia, significantly reducing the discomfort, side-effects and inconvenience associated with frequent drug dosing.”

Veltis technology is a platform of native and engineered human albumins. When combined with a drug candidate it offers the potential for adaptive control of therapeutic half-life. The platform has the potential to significantly improve the treatment options available to haemophilia patients by maintaining the activity levels of therapeutics for prolonged periods and opening the door towards extended dosing intervals.

First generation Veltis technology offers CSL Behring a highly versatile drug delivery platform that improves treatment options and patient quality of life. Albumedix also offers a second generation version of Veltis, presenting new opportunities to optimize the pharmacokinetics and efficacy of peptides, proteins or small molecule drugs.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recently put Idelvion forward for marketing authorization. Approval in the EU and other territories is expected soon.